A MULTICENTER, OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS OF LENALIDOMIDE (REVLIMID® ) IN SUBJECTS WITH MANTLE CELL LYMPHOMA WHO HAVE RELAPSED OR PROGRESSED AFTER TREATMENT WITH IBRUTINIB OR ARE REFRACTORY OR INTOLERANT TO IBRUTINIB - Regional Cancer Care Associates LLC

Clinical Trials

A MULTICENTER, OBSERVATIONAL STUDY TO EVALUATE THE EFFECTIVENESS OF LENALIDOMIDE (REVLIMID® ) IN SUBJECTS WITH MANTLE CELL LYMPHOMA WHO HAVE RELAPSED OR PROGRESSED AFTER TREATMENT WITH IBRUTINIB OR ARE REFRACTORY OR INTOLERANT TO IBRUTINIB

Type of Cancer
Lymphoma
Locations
Hackensack
Sponsor
Celgene
Protocol Number
CC-5013-MCL-004
Cancer Diagnosis
To Learn More Call
201-510-0910